The Latest Breaking News from Medicare

A roundup of the latest of interest to financial advisers includes research on the Great American Retirement Fraud, fearless forecasts, and the problem with Roth conversions in 2022.

The prices are still relentlessly high.

Monoclonal antibodies have emerged as a powerful tool for reducing hospitalization and death from COVID-19, but recently published studies suggests that the lab-created proteins are going to those who need them less — patients with the fewest chronic conditions — while usage in hospital outpatient clinics has followed a persistent…

The drug industry, patient advocates and congressional Republicans have all attacked federal officials’ decision to decline routine Medicare coverage for a controversial Alzheimer’s drug. They’ve gone as far as to accuse them of tacit racism, ageism and discrimination against the disabled — and hinted at a lawsuit — over the…

WASHINGTON — Advocates on both sides of a debate over dramatically restricting Medicare’s coverage of an expensive and controversial Alzheimer’s treatment are waging competing campaigns to influence a final decision in April.

Competing campaigns look to influence the debate over dramatically restricting coverage of a controversial treatment drug Aduhelm.

Mayo Clinic is not scheduling appointments for seniors in certain Medicare Advantage health plans because their insurers haven't negotiated contracts for in-network access to the world-renowned medical center.

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

The House is close to approving a bipartisan bill that would lift onerous budget requirements that have helped push the Postal Service deeply into debt